ARDX$6.87
$6.9086
Chart
Performance
Key Stats
AI ARDX Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyArdelyx shows mixed signals with a strong fundamental outlook, particularly in its financial position and growth, but faces some technical headwinds and a negative earnings trend. The thematic alignment is moderate.
Thematic
Ardelyx operates in the biopharmaceutical sector, focusing on treatments for unmet medical needs, which aligns with broader healthcare innovation themes. However, specific disruptive technology or market dominance themes are less pronounced.
Fundamental
Ardelyx demonstrates a strong balance sheet with increasing assets and manageable liabilities, alongside improving revenue trends and positive gross profit. However, persistent net losses and negative EPS are key concerns.
Technical
The stock shows some bullish short-term momentum with prices trading above key moving averages, but the longer-term trend and momentum indicators suggest a more neutral stance with potential for choppiness.
| Factor | Score |
|---|---|
| Healthcare Innovation | 70 |
| Specialty Pharmaceuticals | 65 |
| Market Demand for Treatments | 50 |
| Regulatory Environment Impact | 40 |
| Competitive Landscape | 50 |
| Factor | Score |
|---|---|
| Valuation | 60 |
| Profitability | 20 |
| Growth | 90 |
| Balance Sheet Health | 85 |
| Cash Flow | 40 |
| Factor | Score |
|---|---|
| Trend Analysis | 70 |
| Momentum | 60 |
| Volume Confirmation | 65 |
| Support & Resistance | 55 |
AI Investing Checklist
Powered by LiveAIBullish Points (8)
Attractive Valuation
The stock's Price-to-Sales (PS) ratio is 3.8, which is considered low for the industry. The company's Price-to-Earnings (PE) ratio on a trailing twelve months (TTM) basis is -29.5, indicating potential undervaluation given recent losses but a forward-looking positive outlook.
Strong Cash Position
The company has a substantial cash and cash equivalents position of $64.93 million as of 2024Q4, providing a cushion against short-term financial needs and supporting ongoing operations.
Bearish Points (7)
Negative Net Income
The company has consistently reported net losses, with a net income of -$39.14 million for the annual period ending 2024Q4. The net margin of -11.7% indicates ongoing profitability challenges.
High Price-to-Sales Ratio
The company's Price-to-Sales (PS) ratio of 3.8 is high relative to its recent revenue performance and negative net income, suggesting a potentially stretched valuation.
Calendar
August 2025
5
Next Earnings Date
H: $-0.11
A: $-0.14
L: $-0.17
H: 90.50M
A: 81.85M
L: 72.50M
Profile
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Seasonals
Price Target
10.82 USD
The 39 analysts offering 1 year price forecasts for ARDX have a max estimate of 15.00 and a min estimate of 8.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 92
Markets Auryxia (ferric citrate), an orally administered phosphate binder, directly competing with Ardelyx's XPHOZAH for the control of serum phosphorus in CKD patients on dialysis.
Weight: 90
Parent company of CSL Vifor, a global leader in nephrology, which markets Velphoro (sucroferric oxyhydroxide), a major phosphate binder competing with Ardelyx's XPHOZAH.
Weight: 90
Commercializes Linzess (linaclotide), a leading prescription treatment for IBS-C, directly competing with Ardelyx's Ibsrela.
Weight: 88
Markets Renvela/Renagel (sevelamer), a widely used calcium-free phosphate binder, directly competing with Ardelyx's XPHOZAH in hyperphosphatemia management.